Panel Rejects Class Action Against Clifford Chance

In the wake of Diagnostic Ventures’ $1.7 billion collapse, investors have won the right to pursue class action fraud claims against the firm’s auditors at Deloitte & Touche but lost a bid to bring class claims against lawyers from Clifford Chance.